Renishaw Diagnostics announces CE marking of RenDx Multiplex

August 2015 – for immediate release
Further information: Jim Greaves, +44 1415 577933
Renishaw Diagnostics announces CE marking of RenDx® Multiplex Assay System and Fungiplex assay
Glasgow, United Kingdom
Renishaw Diagnostics is pleased to announce the launch of the CE-IVD certified RenDx Multiplex Assay
System together with its first assay, Fungiplex, a multiplex PCR in vitro test for the qualitative detection
of Candida and Aspergillus DNA extracted from blood samples.
The assay is designed for use on the RenDx Multiplex Assay System, an automation and detection
platform that allows processing of up to 45 samples in a single run and identifies 12 Candida and
Aspergillus species using a unique detection technology known as surface enhanced resonance Raman
spectroscopy (SERRS).
Rupert Jones, General Manager of Renishaw Diagnostics, said, “The CE-IVD launch of our RenDx
platform and first assay marks a significant milestone, not just in the progress made here at Renishaw
Diagnostics but more importantly, for infectious disease diagnostics throughout Europe. The extensive
target menu for the Fungiplex assay, together with the high sensitivity that can be achieved through
our exceptional detection technology, has the potential to aid earlier diagnosis, reduce overall spend
and improve patient outcomes for those susceptible to these life threatening infections. We are
looking forward to working with clinicians and laboratories to bring this assay into routine clinical use.”
For further information please email [email protected] or visit our website at